Development and validation of a PBPK model of gepotidacinin rats to predict exposure in human prostate
Poster presented at the 34th ECCMID congress in Barcelona (May 2024) - Development and validation of a PBPK model of gepotidacinin rats to predict exposure in human prostate
This AB-DIRECT project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853976. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
By continuing your navigation, you accept the deposit of third-party cookies intended to offer you videos, sharing buttons, content uploads from social platforms. Learn more
Cookies settings
×
Functional Cookies
This site uses cookies to ensure its proper functioning and cannot be deactivated from our systems. We do not use them for advertising purposes. If these cookies are blocked, certain parts of the site will not be able to function.
Measure of audience
This site uses audience measurement and analysis cookies, such as Google Analytics, in order to evaluate and improve our website.
This site uses third-party components, such as NotAllowedScript6772d2a65fc44ReCAPTCHA, Google NotAllowedScript6772d2a65fb19Maps, which may deposit cookies on your machine. If you decide to block a component, the content will not be displayed